Novel Mechanisms of Action in Multiple Sclerosis: Focus on BTK Inhibitors
Experts discuss Bruton's tyrosine kinase (BTK) inhibitors, which block the actions of B cells and may affect other cell types that can facilitate inflammation, recent key clinical data on BTK inhibitors in multiple sclerosis. and how to incorporate these novel agents into treatment plans once they become available.
Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.
EP. 2: BTK Inhibitor Clinical Development
Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.
EP. 3: Phase II Clinical Trial: Evobrutinib
Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.
EP. 4: Phase II Clinical Trial: Fenebrutinib
Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.
EP. 5: Phase II Clinical Trial: Tolebrutinib
Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.
EP. 8: BTKi Mechanism of Action
Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.
EP. 9: BTKi Effect on Chronic Active Lesions
Neurology experts discuss the potential effects of BTKi on chronic active lesions during multiple sclerosis therapies.
EP. 10: BTKi Treatment: Clinical Measures
Experts provide insights about what clinical measures they look for when treating patients with BTKis for multiple sclerosis.
